Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis

References

• KavanaughAFRitchlinCTGRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelinesJ Rheumatol2006331417142116724373
   PubMed Web of Science ®Google Scholar
• SpadaroALubranoEPsoriatic arthritis: imaging techniquesReumatismo20126429910622690386
   PubMedGoogle Scholar
• McHughNJBalachrishnanCJonesSMProgression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective studyRheumatology (Oxford)20034277878312730539
   PubMed Web of Science ®Google Scholar
• LubranoEPerrottaFMCarboniAScarnoAFerraraNSpadaroADisease-modifying antirheumatic drugs or biological blockers in psoriatic arthritis?CML Rheumatology2013327783
   Google Scholar
• SorianoERMcHughNJTherapies for peripheral joint disease in psoriatic arthritis. A systematic reviewJ Rheumatol2006331422143016724372
   PubMed Web of Science ®Google Scholar
• SpadaroATaccariEMohtadiBRiccieriVSensiFZoppiniALife-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugsClin Exp Rheumatol1997156096149444416
   PubMed Web of Science ®Google Scholar
• RicciMDe MarcoGDesiatiFLong term survival of methotrexate in psoriatic arthritisReumatismo20096112513119633799
   PubMedGoogle Scholar
• LieEvan der HeijdeDUhligTEffectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritisAnn Rheum Dis20106967167619740904
   PubMed Web of Science ®Google Scholar
• SalvaraniCPipitoneNMarchesoniAItalian Society for RheumatologyRecommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for RheumatologyClin Exp Rheumatol2011292841
   PubMed Web of Science ®Google Scholar
• SpadaroACeccarelliFScrivoRValesiniGLife-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritisAnn Rheum Dis2008671650165118854519
   PubMed Web of Science ®Google Scholar
• SaadAASymmonsDPNoycePRAshcroftDMRisks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and meta-analysis of randomized controlled trialsJ Rheumatol20083588389018381787
   PubMed Web of Science ®Google Scholar
• AshZGaujoux-VialaCGossecLA systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritisAnn Rheum Dis20127131932621803753
   PubMed Web of Science ®Google Scholar
• SaadAAHyrichKLAshcroftDMDrug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritisExpert Opin Drug Saf20111021922621208138
   PubMed Web of Science ®Google Scholar
• LubranoESpadaroAMarchesoniAThe effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanerceptClin Exp Rheumatol201129808421345296
   PubMed Web of Science ®Google Scholar
• ScarpaRAttenoMLubranoEThe effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot studyClin Rheumatol2011301063106721360007
   PubMed Web of Science ®Google Scholar
• KavanaughATutuncuZCatalan-SanchezTUpdate on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritisCurr Opin Rheumatol20061834735316763453
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJCarmonaLBIOBADASER GroupSwitching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodArthritis Res Ther200681R2916507128
   PubMed Web of Science ®Google Scholar
• CoatesLCCawkwellLSNgNWSustained response to long-term biologics and switching in psoriatic arthritis: results from real life experienceAnn Rheum Dis20086771771918055476
   PubMed Web of Science ®Google Scholar
• BrocqORouxCHAlbertCTNF alpha antagonist continuation rates in 442 patients with inflammatory joint diseaseJoint Bone Spine20077414815417368068
   PubMed Web of Science ®Google Scholar
• OlivieriIde PortuSSalvaraniCPACE working groupThe psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapyRheumatology2008471664167018725374
   PubMed Web of Science ®Google Scholar
• RitchlinCTKavanaughAGladmanDDGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)Treatment recommendations for psoriatic arthritisAnn Rheum Dis2009681387139418952643
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSGaujoux-VialaCEuropean League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapiesAnn Rheum Dis20127141221953336
   PubMed Web of Science ®Google Scholar
• LeipeJGrunkeMDechantCRole of Th17 cells in human autoimmune arthritisArthritis Rheum2010622876288520583102
   PubMed Web of Science ®Google Scholar
• SpadaroALubranoEBeyond anti-TNF-α agents in psoriatic arthritisExpert Rev Clin Immunol2013950750923730881
   PubMed Web of Science ®Google Scholar
• BensonJMSachsCWTreacyGTherapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumabNat Biotechnol20112961562421747388
   PubMed Web of Science ®Google Scholar
• KobayashiMFitzLRyanMIdentification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytesJ Exp Med19891708278452504877
   PubMed Web of Science ®Google Scholar
• TrinchieriGInterleukin-12 and the regulation of innate resistance and adaptive immunityNat Rev Immunol2003313314612563297
   PubMed Web of Science ®Google Scholar
• KleinschekMAMullerUBrodieSJIL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12J Immunol20061761098110616393998
   PubMed Web of Science ®Google Scholar
• TangCChenSQianHHuangWInterleukin-23: as a drug target for autoimmune inflammatory diseasesImmunology201213511212422044352
   PubMed Web of Science ®Google Scholar
• OppmannBLesleyRBlomBNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12Immunity20001371572511114383
   PubMed Web of Science ®Google Scholar
• McKenzieBSKasteleinRACuaDJUnderstanding the IL-23-IL-17 immune pathwayTrends Immunol200627172316290228
   PubMed Web of Science ®Google Scholar
• JanaMPahanKInduction of lymphotoxin-alpha by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70Immunology200912731232519019087
   PubMed Web of Science ®Google Scholar
• IwakuraYIshigameHThe IL-23/IL-17 axis in inflammationJ Clin Invest20061161218122216670765
   PubMed Web of Science ®Google Scholar
• PatelDDLeeDMKolbingerFAntoniCEffect of IL-17 A blockade with secukinumab in autoimmune diseasesAnn Rheum Dis201372Suppl 2S116S123
   Web of Science ®Google Scholar
• FishwildDMO’DonnellSLBengoecheaTHigh-avidity human IgG (kappa)monoclonal antibodies from a novel strain of minilocus transgenic miceNat Biotechnol1996148458519631008
   PubMed Web of Science ®Google Scholar
• LonbergNHuman antibodies from transgenic animalsNat Biotechnol1995231117112516151405
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAPHOENIX 1study investigatorsEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet20083711665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMfor PHOENIX 2 study investigatorsEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar
• GriffithsCEStroberBEvan de KerkhofPACCEPT Study GroupComparison of ustekinumab and etanercept for moderate-to-severe psoriasisN Engl J Med201036211812820071701
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialLancet200937363364019217154
   PubMed Web of Science ®Google Scholar
• McInnesIBKavanaughAGottliebABPSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet201338278078923769296
   PubMed Web of Science ®Google Scholar